This weekend, Break Through Cancer Chief Science Officer @boehmjesse.bsky.social will deliver the opening keynote at the AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers.

If you missed our live discussion, you can now watch the recording of Breaking Through Pancreatic Cancer with Revolution Medicines on demand.

Breaking Through Pancreatic Cancer with Revolution Medicines - Break Through Cancer

A breakthrough in pancreatic cancer is making headlines. This is a conversation about the science behind it and what comes next for patients with Mark Goldsmith, MD, PhD, of Revolution Medicines and…

breakthroughcancer.org

Functional precision medicine has enormous potential to improve how we match the right cancer therapies to the right patients. This week, our Chief Scientific Officer @boehmjesse.bsky.social is participating in the National Cancer Institute's Precision in Practice workshop

What's next for KRAS-targeted therapies? We're investing $16M with @break-cancer.bsky.social & the Cinelli Family Foundation to unite six leading institutions to find out! 💜 Read the FULL release: lfdn.org/KRAS_2

At an exciting moment for pancreatic cancer, Break Through Cancer, and @lustgarten.org, with support from the Cinelli Family Foundation are investing $16 million to help define what's next for this deadly disease.

Minimal residual disease remains one of the biggest challenges in #OvarianCancer. At #ASCO2026, Dr Helen Clark from our Targeting MRD in Ovarian Cancer TeamLab presents work evaluating how ctDNA may enhance detection of high-risk minimal residual disease.

Important moment for #PancreaticCancer at today's #ASCO2026 plenary Dr. Brian Wolpin presents final analysis from the Phase 3 RASolute 302 study evaluating daraxonrasib in previously treated metastatic PDAC. Encouraging to see these advances from RevMed to improve outcomes for patients.

Few targets have required more persistence than #KRAS. At #ASCO2026, the @AACR / @ASCO joint session, The KRAS Journey—Perseverance Pays Off, brings together leaders from across the field to reflect on decades of discovery and the advances now reaching patients.

. #ASCO2026 kicks off today. It’s always exciting when the cancer research community comes together to share new science, challenge ideas, and learn from one another. We look forward to following the advances emerging from this year’s meeting.

This week, the Accelerating #Glioblastoma Therapies Through Serial Biopsies TeamLab are meeting in person to dive into the data—from clinical outcomes, tumor evolution, immune response, spatial biology, and metabolomics—to shape publications, moving these insights into the #CancerResearch community.

An energizing week at #AACR26 for 𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋. We’re proud to support this community and the science they are driving forward. For our AACR recap and other updates, join our newsletter: breakthroughcancer.org/2026/04/subs...

Subscribe for updates - Break Through Cancer

Explore Break Through Cancer’s 2025 Year in Review highlighting clinical trials, breakthrough research, data science innovation, and radical collaboration across glioblastoma, AML, ovarian,…

breakthroughcancer.org

The final day of #AACR2026 posters to catch. From #Glioblastoma oncolytic virus therapy (Abstract 7743) to #PancreaticCancer RAS biology (Abstract7330) and large-scale #CancerGenomics (Abstract 7274), these BTC posters highlight how deeper understanding is shaping precise cancer treatment.

.#LiquidBiopsy is changing how we think about and quantify MRD. At #AACR2026, Valsamo Anagnostou presents advances in ctDNA approaches to detect, characterize, and address MRD, an area with major implications for earlier intervention and more precise cancer care. ADT04 |Ballroom 6A | 10.45am

Personalized medicine is the future for ALK+ #LungCancer and data science is how we get there. Exciting work from our collaborators at @mdanderson.bsky.social on digital twins using #AI to model patient outcomes & guide treatment decicions. MS.BC02.01 |Ballroom 20 | 3.05pm

In the Late Breaking session (LBMS01) Revolution Medicines highlights progress in RAS(ON) inhibition. It is an exciting time for RAS-targeted therapy in #PancreaticCancer LBM201 | Room 5 Upper Level | 2.30pm

. #PancreaticCancer research is at a turning point with major advances in treatments, biology, and early interception. Today PIs across our PDAC TeamLabs, Shubham Pant, Will Freed-Pastor, and @anirbanmaitra.bsky.social present on therapeutic advances, cryptic antigens, and early detection. AOS10

Exciting data from the our Accelerating GBM Therapies Through Serial Biopsies TeamLab at #AACR26: New #AI-driven approaches are advancing how we analyze imaging in #Glioblastoma to support precise, scalable tumor characterization from radiology data. PO.BCS02.04 | 2-5pm

Understanding clonal hematopoiesis could unlock #EarlyDetection and prevention of AML. Dr. Benjamin Ebert of @danafarber.bsky.social and a leader in our AML TeamLab presents on CHIP, inflammation, and AML developments this morning at #AACR26 SY10 | Room 30 Upper Level | 11.10

Understanding #Glioblastoma means mapping tumor architecture in high definition. At #AACR26, TeamLab PI Mario Suva presents on spatial analysis of GBM, advancing how we map tumor architecture, heterogeneity, and the biology that shapes treatment response. AOS04 | Room 15 Mezz Level | 10.15am

The biggest opportunities in #OvarianCancer are in #EarlyDetection and #Prevention. At #AACR26, Drs Rebecca Stone, Angela Belcher, and @rdrapkin8-penn.bsky.social present a field-shaping session spanning surgical prevention to, imaging that detects tubal precursors, and the pre-cancer atlas AOS09

AI can reshape how we study cancer biology - this is the topic of today's plenary at #AACR26 SAB member @bowang87.bsky.social speaks to foundation models that can reason across complex biological systems and where #AI in #Cancer Research is headed

Sunday at #AACR26 and the science continues. Work from our GBM TeamLab highlights a key challenge in #Glioblastoma: biomarker signatures vary across patients—and even within the same tumor over time (abstract 1055) Looking forward to bringing our community together this evening at the BTC Social

Residual disease is in focus at the opening #AACR2026 plenary Aaron Hata @mgbresearch.bsky.social will highlight work from the PoweRD 2 Cure ALK+ Lung Cancer TeamLab on MRD in lung cancer—underscoring how collaborative, preclinical science is shaping our understanding of MRD. #AACR26

Today at #AACR2026, our SAB member Dr Robert Winn highlighted patient-centered approaches to bringing trials closer to the communities they serve. Dr. Winn echoes our goal to ensure the science we support drives better outcomes for all patients.

Exciting work coming out of the 𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋 community over the coming days at #AACR2026. From work advancing earlier detection, deeper understanding of tumor biology, to more precise approaches to treatment. Sure to be a great meeting - @theaacr.bsky.social

Congratulations to the Revolution Medicines team on the important results from the RASolute302 Phase 3 clinical study of daraxonrasib in advanced #PancreaticCancer. As progress accelerates in targeting KRAS-driven tumors, the next step is understanding the effects of these therapies in patients.

Congratulations to @boehmjesse.bsky.social, our Chief Science Officer, and @broadinstitute.org's DepMap team on their 2026 @theaacr.bsky.social Scientific Achievement Award. This team is honored for systematically mapping genetic dependencies across cancer cells to uncover specific vulnerabilities

Congratulations to members 𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋 community members named as Fellows of the @theaacr.bsky.social Academy Class of 2026! Cory Abate-Shen, Christina Curtis, Ross Levine (@rosslevinemd.bsky.social), William (Bill) Nelson, Alice Shaw, & Matthew Vander Heiden. www.aacr.org/about-the-aa...

𝗘𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗶𝘀 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝘀𝘁 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝘁𝗼 𝗰𝗵𝗮𝗻𝗴𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀. This year we committed $2M in partnership with @themarkfdn.bsky.social, @theaacr.bsky.social, @lustgarten.org, and @tinaswish.bsky.social to support the development of new approaches to detect deadly cancers earlier.

𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋 and our president Tyler Jacks are featured in @cancerletter.com today. The story highlights our model of Radical Collaboration™ and how we’re aligning institutions and scientists to accelerate progress against the deadliest cancers. cancerletter.com/conversation...

Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.” - The Cancer Letter

Five years ago, Tyler Jacks took on a new challenge, becoming president of Break Through Cancer, a foundation that has pledged to spend at least $500 million to support research projects across top ti...

cancerletter.com